Asher Biotherapeutics, a pioneering biotechnology company located in South San Francisco, has successfully secured a funding round, raising an impressive $55 million. Specializing in the development of precisely targeted immunotherapies for cancer and various other diseases, Asher Bio is revolutionizing the field with its powerful cis-targeting platform. This innovative technology enables the selective activation of specific immune cell types, overcoming the limitations of traditional immunotherapies that have broader effects. By harnessing the potential to precisely direct various immune mediators against specific immune cell types, Asher Bio aims to create cutting-edge immunotherapies for cancer, autoimmune disorders, and infectious diseases. The funding, supported by Third Rock Ventures, will further empower Asher Bio to advance its groundbreaking research and propel its mission to provide superior treatment options for patients in need.
Breaking News: Asher Biotherapeutics Secures $55 Million in Series C Funding for Precision Immunotherapies
Recently funded 路 $55.0M Series cBiotechnology
Get the full Asher Biotherapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series c rounds
Companies that recently closed a Series c round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  SOLIVIS | Series c | $16.0M | 1d ago |
| 2 |  SKAN Switzerland | Series c | $63.0M | 1d ago |
| 3 |
